Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.dalton.com
Number of Employees: 80
Year Founded: 1986
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Dalton Chemical Laboratories Inc. provides cGMP contract services. The company’s services include integrated chemistry, drug development, and dosage form manufacturing. It also offers medicinal chemistry, process development, reaction optimization, formulation development, analytical testing and development, and cGMP manufacturing services, such as cGMP API production and cGMP sterile filling including sterile powder filling. The company caters to pharmaceutical dosage form manufacturing, pharmaceutical ingredient manufacturing, chemical manufacturing, development services, research services, and biotechnology sectors. Dalton Chemical Laboratories Inc. was founded in 1986 and is based in Toronto, Canada. As of March 24, 2020, Dalton Chemical Laboratories Inc. operates as a subsidiary of Seikagaku Corporation.


Financial Information (Currency: CAD, in mm)
Total Revenue
 31.1
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 80
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Pekos, Peter 
Founder, Chief Executive Officer and President


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
349 Wildcat Road | Toronto, ON | M3J 2S3 | Canada
Phone: 416-661-2102   Fax: 416-661-2108

Parent Company
Seikagaku Corporation (TSE:4548)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-28-2020
Mar-24-2020
Merger/Acquisition
Target
Dalton Chemical Laboratories Inc.
Seikagaku Corporation (TSE:4548)

30.56
Sep-17-2007
Nov-27-2007
Merger/Acquisition
Seller
DDP Therapeutics, Inc.
Critical Outcome Technologies Inc. (nka:Cotinga Pharmaceuticals Inc. (OTCPK:COTQ.F))
Dalton Chemical Laboratories Inc.
6.25
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-05-2023
Company Conference Presentations
Dalton Chemical Laboratories Inc. Presents at BIO International Convention 2023, Jun-05-2023
Feb-16-2023
Business Expansions
Dalton Pharma Services Announces Major Expansion in Commercial Sterile Manufacturing Capacity
Feb-19-2021
Client Announcements
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Aug-18-2020
Client Announcements
Tetra Bio-Pharma Inc. Engages Dalton Pharma Services for GMP Manufacturing of ARDS-003
Mar-24-2020
M&A Transaction Closings
Seikagaku Corporation (TSE:4548) completed the acquisition of Dalton Chemical Laboratories Inc. from individuals.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 12:38 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
84
GlobalData

Sep 21, 2023 05:43 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
36
GlobalData

Jun 22, 2023 03:19 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
36
GlobalData

Dec 13, 2022 03:11 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
84
GlobalData

Sep 21, 2022 05:12 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
84
GlobalData

Jun 15, 2022 01:15 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
83
GlobalData

Jun 15, 2022 12:28 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
37
GlobalData

Mar 16, 2022 02:47 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
83
GlobalData

Feb 23, 2022 04:58 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
37
GlobalData

Dec 16, 2021 12:46 AM
Dalton Chemical Laboratories Inc.
Dalton Pharma Services
Reports
42


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Contract Chemistry Services, Contract Development and Manufacturing Services, Formulation Development Services


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Aug-14-2018
Dalton Chemical Laboratories Inc.
SEDAR
News Releases
32 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Pekos, Peter 
Founder, Chief Executive Officer and President
416-661-2102
416-661-2108

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
